key: cord-0707143-n4wg5xht
authors: Wilson, Julie; Shankar-Hari, Manu
title: Immunological subpopulations within critically ill COVID-19 patients
date: 2021-02-18
journal: Chest
DOI: 10.1016/j.chest.2021.01.023
sha: f992129ecb8351fc9fc8c1f0cf39259d95e44b6b
doc_id: 707143
cord_uid: n4wg5xht

nan

is also associated with inborn errors in the interferon pathway, and antibodies to interferons. 8, 9 Furthermore, the effector immune responses associated with helminth J o u r n a l P r e -p r o o f infections 6 and with extracellular pathogens (bacterial and fungal infections) 6 appear activated, and persist in patients with severe COVID-19 illness. 3 In this context, let us consider the cohort study by Dupont and colleagues. 10 Second, hyper-inflammatory phenotype, characterized by pan T cell lymphopenia, and highest cytokines levels, was most prevalent in patients receiving mechanical ventilation.

Third, complement-dependent phenotype characterized by highest complement protein levels. The overall critical care mortality was 31%, with the highest mortality in the hyperinflammatory phenotype and least in the complement-dependent phenotype. The authors conclude that these phenotypes should inform eligibility criteria for clinical trials testing immunomodulation.

When contextualizing this work, the key limitations to consider include are a single center study, without an independent validation cohort and with immunological assessments only at

A minimal common outcome measure set for COVID-19 clinical research. The Lancet Infectious Diseases

Extrapulmonary manifestations of COVID-19

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Type I and Type III Interferons -Induction, Signaling, Evasion, and Application to Combat COVID-19

The 3 major types of innate and adaptive cellmediated effector immunity

Genetic mechanisms of critical illness in Covid-19

Inborn errors of type I IFN immunity in patients with lifethreatening COVID-19

Auto-antibodies against type I IFNs in patients with lifethreatening COVID-19

Identification of distinct immunophenotypes in critically-ill COVID-19 patients